Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.61
VVUS's Cash to Debt is ranked higher than
60% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. VVUS: 1.61 )
VVUS' s 10-Year Cash to Debt Range
Min: 1.61   Max: No Debt
Current: 1.61

Equity to Asset 0.36
VVUS's Equity to Asset is ranked higher than
54% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VVUS: 0.36 )
VVUS' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.94
Current: 0.36

0.3
0.94
F-Score: 5
Z-Score: -1.27
M-Score: 35.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -190.69
VVUS's Operating margin (%) is ranked higher than
63% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. VVUS: -190.69 )
VVUS' s 10-Year Operating margin (%) Range
Min: -25600   Max: 38.44
Current: -190.69

-25600
38.44
Net-margin (%) -215.16
VVUS's Net-margin (%) is ranked higher than
62% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. VVUS: -215.16 )
VVUS' s 10-Year Net-margin (%) Range
Min: -22800   Max: 43.53
Current: -215.16

-22800
43.53
ROE (%) -113.75
VVUS's ROE (%) is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. VVUS: -113.75 )
VVUS' s 10-Year ROE (%) Range
Min: -370.05   Max: 45.31
Current: -113.75

-370.05
45.31
ROA (%) -40.40
VVUS's ROA (%) is ranked higher than
63% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. VVUS: -40.40 )
VVUS' s 10-Year ROA (%) Range
Min: -148.41   Max: 27.34
Current: -40.4

-148.41
27.34
ROC (Joel Greenblatt) (%) -505.24
VVUS's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. VVUS: -505.24 )
VVUS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29695.48   Max: 103.31
Current: -505.24

-29695.48
103.31
EBITDA Growth (%) 20.00
VVUS's EBITDA Growth (%) is ranked higher than
93% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. VVUS: 20.00 )
VVUS' s 10-Year EBITDA Growth (%) Range
Min: -48.5   Max: 66.1
Current: 20

-48.5
66.1
EPS Growth (%) 23.00
VVUS's EPS Growth (%) is ranked higher than
92% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. VVUS: 23.00 )
VVUS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 185.4
Current: 23

0
185.4
» VVUS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

VVUS Guru Trades in Q1 2013

Jean-Marie Eveillard 200,000 sh (New)
Louis Moore Bacon 100,000 sh (New)
Steven Cohen 150,100 sh (+1976.36%)
Alan Fournier 400,000 sh (+60%)
Chuck Royce 500,000 sh (+42.86%)
John Burbank 9,554,858 sh (+6.9%)
Kyle Bass Sold Out
» More
Q2 2013

VVUS Guru Trades in Q2 2013

Alan Fournier 735,504 sh (+83.88%)
Chuck Royce 500,000 sh (unchged)
Kyle Bass 6,686 sh (unchged)
Jean-Marie Eveillard Sold Out
Louis Moore Bacon Sold Out
John Burbank 8,505,148 sh (-10.99%)
Steven Cohen 2,900 sh (-98.07%)
» More
Q3 2013

VVUS Guru Trades in Q3 2013

Chuck Royce 500,000 sh (unchged)
John Burbank 500,000 sh (unchged)
Steven Cohen Sold Out
Alan Fournier 711,400 sh (-3.28%)
John Burbank 5,425,000 sh (-36.22%)
» More
Q4 2013

VVUS Guru Trades in Q4 2013

Paul Tudor Jones 29,151 sh (New)
John Burbank 5,925,000 sh (+9.22%)
Alan Fournier 570,800 sh (-19.76%)
Chuck Royce 258,000 sh (-48.4%)
» More
» Details

Insider Trades

Latest Guru Trades with VVUS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-12-31 Add 9.22%0.15%$8.235 - $11.19 $ 5.25-46%5925000
John Burbank 2013-09-30 Reduce -36.22%1.27%$9.45 - $14.99 $ 5.25-58%5425000
John Burbank 2013-06-30 Reduce -10.99%0.46%$10.43 - $15.1 $ 5.25-59%8505148
Jean-Marie Eveillard 2013-06-30 Sold Out 0.01%$10.43 - $15.1 $ 5.25-59%0
John Burbank 2013-03-31 Add 6.9%0.27%$10.2 - $14.87 $ 5.25-58%9554858
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$10.2 - $14.87 $ 5.25-58%200000
John Burbank 2012-12-31 Add 21.15%0.8%$10.24 - $22.86 $ 5.25-64%8938268
George Soros 2012-09-30 Sold Out 0.06%$17.81 - $29.93 $ 5.25-78%0
John Burbank 2012-06-30 Add 10.12%0.73%$21.5 - $28.68 $ 5.25-78%8136600
George Soros 2012-06-30 Reduce -64.93%0.09%$21.5 - $28.68 $ 5.25-78%150000
John Burbank 2012-03-31 Add 72.22%2.35%$9.99 - $23.78 $ 5.25-65%7388793
George Soros 2012-03-31 New Buy0.14%$9.99 - $23.78 $ 5.25-65%427750
George Soros 2011-03-31 Sold Out $6.06 - $11.2 $ 5.25-34%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Vivus

Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS
According to GuruFocus list of three-year lows; Vivus, Rally Software Development Corp., Wi-Lan Inc. and Covisint Corp. have all reached their three-year lows. Read more...
Unique Investor Kyle Bass Unloads Five
Investor J. Kyle Bass is truly unique. What differentiates the principal of Hayman Advisors from other super investors? He’s politically connected but reportedly does not vote and does not read the local newspaper, according to D Magazine. Kyle Bass is also well known for his investment analysis of the subprime crisis and is reported to have made around a half a billion dollars betting against subprime CDOs at a time when very few people could understand what CDOs are. Read more...

Ratios

vs
industry
vs
history
P/B 3.50
VVUS's P/B is ranked higher than
73% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. VVUS: 3.50 )
VVUS' s 10-Year P/B Range
Min: 1.71   Max: 17.4
Current: 3.5

1.71
17.4
P/S 6.60
VVUS's P/S is ranked higher than
68% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. VVUS: 6.60 )
VVUS' s 10-Year P/S Range
Min: 2.04   Max: 694.5
Current: 6.6

2.04
694.5
EV-to-EBIT 15.60
VVUS's EV-to-EBIT is ranked higher than
68% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. VVUS: 15.60 )
VVUS' s 10-Year EV-to-EBIT Range
Min: 17.1   Max: 51.7
Current: 15.6

17.1
51.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.20
VVUS's Price/Net Cash is ranked higher than
57% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. VVUS: 8.20 )
VVUS' s 10-Year Price/Net Cash Range
Min: 3.3   Max: 111.25
Current: 8.2

3.3
111.25
Price/Net Current Asset Value 5.40
VVUS's Price/Net Current Asset Value is ranked higher than
76% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. VVUS: 5.40 )
VVUS' s 10-Year Price/Net Current Asset Value Range
Min: 2.84   Max: 19.48
Current: 5.4

2.84
19.48
Price/Tangible Book 3.50
VVUS's Price/Tangible Book is ranked higher than
76% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. VVUS: 3.50 )
VVUS' s 10-Year Price/Tangible Book Range
Min: 1.39   Max: 10.21
Current: 3.5

1.39
10.21
Price/Median PS Value 0.80
VVUS's Price/Median PS Value is ranked higher than
77% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. VVUS: 0.80 )
VVUS' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 83.88
Current: 0.8

0.14
83.88
Earnings Yield (Greenblatt) 6.40
VVUS's Earnings Yield (Greenblatt) is ranked higher than
71% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. VVUS: 6.40 )
VVUS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 6.8
Current: 6.4

1.9
6.8
Forward Rate of Return (Yacktman) 25.66
VVUS's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. VVUS: 25.66 )
VVUS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.5   Max: -4.2
Current: 25.66

-7.5
-4.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VIU.Germany
VIVUS was incorporated in 1991 as a California corporation and reincorporated in 1996 as a Delaware corporation. The Company is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. Its drug, Qsymia (formerly known as Qnexa) was approved by the FDA for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index, or BMI, of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It has completed Phase 2 clinical studies for Qsymia for the treatment of sleep apnea and Qsymia for the treatment of type 2 diabetes. Its drug, STENDRA, or avanafil, was approved by the FDA for the treatment of erectile dysfunction, or ED, in the U.S. Qsymia for the treatment of chronic weight management competes with several approved anti-obesity drugs including, Belviq (lorcaserin), Arena Pharmaceutical's approved anti-obesity compound to be marketed by Eisai Inc., Eisai Co., Ltd.'s U.S. subsidiary; Xenical (orlistat), marketed by Roche; alli, the over-the-counter version of orlistat, marketed by GlaxoSmithKline; and Suprenza (phentermine hydrochloride), marketed by Akrimax Pharmaceuticals, LCL. In addition to laws and regulations enforced by the FDA, it are also subject to regulation under National Institutes of Health guidelines as well as under the Controlled Substances Act, the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state or local laws and regulations, as its research and development may involve the controlled use of hazardous materials, chemicals, viruses and various radioactive compounds. In addition to regulations in the U.S., it is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its investigational drug candidates.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide